CurrentUnitedHealthcarePolicy CS2O25DOO81N

Intra-articular Sodium Hyaluronate (Viscosupplementation) for Knee Osteoarthritis

This policy governs medical benefit coverage and authorization criteria for intra-articular sodium hyaluronate (hyaluronan) products for knee osteoarthritis and related indications for UnitedHealthcare members; it specifies diagnosis-specific criteria, product preference rules, dosing per FDA labeling, and excluded indications.

Policy Summary

PayerUnitedHealthcare

PolicyIntra-articular Sodium Hyaluronate (Viscosupplementation) for Knee Osteoarthritis

Policy CodePolicy CS2O25DOO81N

Change TypeRoutine reviewno material content changes

Effective DateJul 1, 2025

Next Review Date

Key ActionObtain prior authorization documenting diagnosis of knee osteoarthritis, failed conservative therapy (≥3 months) or intolerance, symptom severity, and product/regimen consistent with FDA labeling.

SourceLink

POLICY UPDATE CHANGES

07/01/2025, Summary of Changes = Routine review; no content changes Archived previous policy version CS2O24DOO81M

knee OAPrimary covered indication

>=6 monthsMinimum interval between treatment courses

18+Products listed

excludedCosmetic use classification

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Policy revision date

Coverage Determinations and Clinical Criteria

Initial Authorization (Sodium Hyaluronate-Naive Patients)

Intra-articular injections of sodium hyaluronate are medically necessary when ALL of the following are met for initial authorization (sodium hyaluronate–naive patients):

Initial authorization criteria: 1) Diagnosis of knee osteoarthritis; 2) Member has not responded adequately to conservative therapy (e.g., physical therapy, NSAIDs, acetaminophen, topical capsaicin) or intra-articular corticosteroid injection with no functional improvement after at least 3 months, or cannot tolerate conservative therapy due to adverse effects; 3) Pain is attributable to degenerative joint disease/primary osteoarthritis of the knee; 4) Member reports pain that interferes with functional activities (e.g., ambulation, prolonged standing); 5) No contraindications to injections (e.g., active joint infection, bleeding disorder); 6) Dosing is in accordance with U.S. FDA‑approved labeling for the requested product.

Reauthorization/Continuation

Reauthorization/Continuation criteria — repeated courses may be considered when ALL of the following are met:

Reauthorization/Continuation: 1) Diagnosis of knee osteoarthritis; 2) Documentation of positive clinical response to the prior hyaluronan therapy (e.g., significant pain relief and functional improvement); 3) At least 6 months have passed since the prior course of treatment for the same joint; 4) Pain has recurred and is interfering with function; 5) Dosing is in accordance with U.S. FDA‑approved labeling for the requested product; 6) Continuing authorization is for a single‑injection course once per joint for a 6‑month period, consistent with the product’s labeled regimen.

Preferred Product Criteria

Preferred product criteria — use preferred products or document exceptions:

Preferred product coverage: Coverage for GenVisc 850, Hyalgan, Supartz, Visco‑3, Hymovis, Orthovisc, Synvisc/Synvisc‑One, Gel‑One, Monovisc, Triluron, TriVisc, or Synojoynt is contingent on Preferred Product Criteria: member must have trialed and had inadequate response to the preferred products (Durolane, Euflexxa, GELSYN‑3), OR physician documents attestation that the requested product is expected to be clinically superior or that the member has contraindication/intolerance to the preferred products. Documentation of prior trial (agent, dose, duration) or physician attestation must be provided.

Coverage considerations by indication

Evidence-based coverage considerations vary by anatomic indication; coverage is contingent on demonstrated clinical benefit supported by robust evidence for that site.

Temporomandibular joint (TMJ): Sodium hyaluronate is not FDA‑labeled for TMJ. Some RCTs and systematic reviews report potential benefit for TMJ OA or disc disorders but overall evidence is insufficient and additional well‑designed trials are needed; HA has not been shown to be superior to other active treatments in available studies.

Shoulder (glenohumeral/rotator cuff): Systematic reviews and RCTs report pain and functional improvements with intra‑articular HA in some studies, but heterogeneity and placebo effects are noted; further randomized trials are necessary to define efficacy and dosing.

Hip: Evidence for hip OA is mixed: some nonrandomized series suggest delayed need for THR in selected patients, but placebo‑controlled RCTs (e.g., Richette) found no benefit versus placebo; some guidelines recommend against IA HA for hip OA.

Ankle:

Coverage considerations and criteria

Coverage considerations and clinical context summarized from device labeling and professional society guidance

Conservative therapy prior to HA for OA: Patients considered for intra‑articular HA for knee OA should have failed conservative therapy (exercise and simple analgesics) prior to HA, consistent with FDA labeling and guideline context.failed conservative therapy

FDA labeling lists single‑ and multi‑injection regimens for patients who have failed conservative therapy.

Joint‑specific guideline stance: Professional society guidance is mixed: ACR conditionally recommends against IA HA for knee and first CMC joint OA (permits shared decision‑making) and strongly recommends against hip OA; AAOS does not support routine viscosupplementation for knee OA. These positions should inform shared decision‑making and coverage determinations.

Use of HA should follow shared decision‑making and consider limited evidence of benefit.

Vocal fold injections: HA injection laryngoplasty may improve voice and quality of life in unilateral vocal fold paralysis with generally low complication rates; benefits are often temporary (approximately 4–6 months reported for cross‑linked preparations) and repeat injections may be required.

Intra‑articular injections of sodium hyaluronate for indications other than knee osteoarthritis are considered unproven and not medically necessary due to insufficient evidence of efficacy. Examples explicitly listed include temporomandibular joint (TMJ) osteoarthritis and TMJ disc displacement, and hip osteoarthritis where randomized, placebo‑controlled trials have failed to consistently demonstrate benefit.

Use of hyaluronic acid gel preparations to improve the skin’s appearance, fill contours, reduce depressions (including acne scars), or treat wrinkles is classified as cosmetic and is excluded from coverage.

Sodium hyaluronate injected for skin/dermal cosmetic indications (e.g., contouring, wrinkle reduction, scar filling) is not a functional medical treatment and is therefore not covered under this policy.

Specific non‑knee intra‑articular uses lack consistent supporting evidence and are listed as examples of not medically necessary care. For TMJ disorders, available randomized and controlled trials are limited and generally do not show superiority over alternative active treatments. For the hip and ankle, retrospective series and small trials provide mixed or low‑quality data and at least one placebo‑controlled RCT in hip OA found no benefit versus placebo; consequently these non‑knee joint applications (including TMJ, hip, and ankle) are considered unproven.

Evidence for intra‑articular hyaluronate in hip and ankle osteoarthritis is limited and inconsistent. A multicenter placebo RCT in hip OA showed no difference between HA and placebo, and ankle OA studies are small with low‑quality outcomes; guideline bodies (for example AAOS/ACR guidance and NICE statements cited in device and guideline summaries) do not support routine viscosupplementation for these joints. Given the mixed and insufficient data, use in hip or ankle OA is not routinely supported by this policy.

Routine viscosupplementation is addressed inconsistently across professional guidance. FDA‑approved sodium hyaluronate products provide labeled single‑ and multi‑injection regimens for knee OA and are intended for use after failure of conservative therapy, but major societies report mixed recommendations: the AAOS does not support routine viscosupplementation for knee OA and the ACR conditionally recommends against IA HA for certain joints and strongly recommends against hip use. Because evidence of meaningful, consistent benefit is variable, clinical use should follow labeled dosing, documented prior conservative therapy, and shared decision‑making.

Procedural, Drug, and Diagnosis Codes

Procedure CPT CodesCPT

20605	Arthrocentesis, aspiration and/or injection, intermediate joint or bursa; without ultrasound guidance.
20606	Arthrocentesis, aspiration and/or injection, intermediate joint or bursa; with ultrasound guidance; with permanent recording and reporting.
20610	Arthrocentesis, aspiration and/or injection, major joint or bursa; without ultrasound guidance.
20611	Arthrocentesis, aspiration and/or injection, major joint or bursa; with ultrasound guidance; with permanent recording and reporting.

Drug J-codesHCPCS

J7318	Hyaluronan or derivative, Durolane, for intra-articular injection, 1 mg.
J7320	Hyaluronan or derivative, GenVisc 850, for intra-articular injection.
J7321	Hyaluronan or derivative, Hyalgan, Supartz or Visco-3, for intra-articular injection, per dose.
J7322	Hyaluronan or derivative, Hymovis, for intra-articular injection.
J7323	Hyaluronan or derivative, Euflexxa, for intra-articular injection, per dose.
J7324	Hyaluronan or derivative, Orthovisc, for intra-articular injection, per dose.
J7325	Hyaluronan or derivative, Synvisc or Synvisc-One, for intra-articular injection.
J7326	Hyaluronan or derivative, Gel-One, for intra-articular injection, per dose.
J7327	Hyaluronan or derivative, Monovisc, for intra-articular injection, per dose.
J7328	Hyaluronan or derivative, GELSYN-3, for intra-articular injection, 0.1 mg.

1–10 of 14

1/2

Diagnosis ICD-10 CodesICD-10

M17.0	Bilateral primary osteoarthritis of knee.
M17.10	Unilateral primary osteoarthritis, unspecified knee.
M17.11	Unilateral primary osteoarthritis, right knee.
M17.12	Unilateral primary osteoarthritis, left knee.
M17.30	Unilateral post-traumatic osteoarthritis, unspecified knee.
M17.31	Unilateral post-traumatic osteoarthritis, right knee.
M17.32	Unilateral post-traumatic osteoarthritis; left knee.
M17.4	Other bilateral secondary osteoarthritis of knee.
M17.5	Other unilateral secondary osteoarthritis of knee.
M17.9	Osteoarthritis of knee, unspecified.

1–10 of 11

1/2

No explicit codes listed in this document sectionmixed

No codes listed

Device/Products listed (informational, not billing codes)mixed

Synvisc	Synvisc - FDA-approved HA preparation; labeling: 3 injections (Synvisc) / single-injection (Synvisc One).
Euflexxa	Euflexxa - FDA-approved HA preparation; labeling: 3 injections.
Hyalgan	Hyalgan - FDA-approved HA preparation; labeling: 5 injections.
Supartz	Supartz - FDA-approved HA preparation; labeling: 3-5 injections.
Visco-3	Visco-3 - FDA-approved HA preparation; labeling: 3 injections.
Hymovis	Hymovis - FDA-approved HA preparation; labeling: 2 injections.
Orthovisc	Orthovisc - FDA-approved HA preparation; labeling: 3-4 injections.
Gel-One	Gel-One - FDA-approved HA preparation; labeling: single injection.
Synvisc One	Synvisc One - FDA-approved HA preparation; labeling: single injection.
Monovisc	Monovisc - FDA-approved HA preparation; labeling: single injection.

1–10 of 16

1/2

Conservative therapy trial duration

Minimum conservative therapy durationAt least 3 months of conservative therapy (e.g., physical therapy, NSAIDs, acetaminophen, topical capsaicin) or intra‑articular steroid with no functional improvement

Acceptable alternatives to meet trial requirementInadequate response to intra‑articular steroid injection may satisfy conservative therapy trial if no functional improvement after ≥3 months

Intolerance optionMember unable to tolerate conservative therapy because of adverse side effects may meet the requirement

Minimum interval between courses

Minimum interval for reauthorizationAt least 6 months must have passed since the prior course of treatment for the same joint

Prior Authorization, Documentation, and Step Therapy

Prior Authorization

Prior Authorization Required

Prior authorization is required for intra-articular (IA) hyaluronic acid (HA) / sodium hyaluronate injections for knee osteoarthritis in accordance with UnitedHealthcare plan rules. Verify and obtain prior authorization before administering IA-HA products; authorization requirements may vary by product and regimen.

Applies to all sodium hyaluronate IA products (single- and multi-injection regimens).
Authorization is required for initial and repeat courses per plan policy and FDA-labeled dosing intervals.

Documentation Required

Required Diagnostic and Severity Documentation

When requesting prior authorization for IA-HA injections, include documentation of diagnostic severity and prior conservative therapy. Typical required documentation includes Visual Analog Scale (VAS) pain score, Kellgren/Lawrence radiographic grade, and evidence of failure or intolerance to conservative measures.

Document VAS pain score (e.g., baseline and change with prior therapy).

Background and Clinical Context

Sodium hyaluronate (hyaluronic acid, or HA) is a naturally occurring component of synovial fluid that contributes to joint lubrication and viscoelasticity. Intra‑articular HA products were developed as viscosupplementation to supplement joint lubrication in osteoarthritis—most extensively studied and labeled for the knee—and differ by molecular weight, cross‑linking, and source. Clinical trials and systematic reviews report mixed results: some studies demonstrate modest symptomatic or functional improvement versus placebo or other active comparators at certain time points, while overall evidence is heterogeneous and not uniformly supportive across joints or products.

Key Terms and Abbreviations

HA (sodium hyaluronate/hyaluronan)

DefinitionSodium hyaluronate (also called hyaluronic acid or hyaluronan) — a component of normal synovial fluid that lubricates joints and absorbs shock

Commercial preparationsCommercial HA products differ by molecular weight and cross‑linking and may be derived from bacterial fermentation or avian sources

Mechanism (clinical context)IA injections of HA replace or supplement synovial fluid to improve joint lubrication and shock absorption

FDA labeled dosing (examples)

Dosing varies by productFDA‑labeled course of treatment per joint differs by product (examples: Durolane = single injection; Euflexxa/Synvisc = 3 injections; Hyalgan = 5 injections)

Range of labeled regimensSome products are single‑injection (Gel‑One, Monovisc, Synvisc One, Durolane), others are multi‑injection (GenVisc 850: 3–5; Orthovisc: 3–4; Supartz: 3–5)

Policy Updates and Revision History

07/01/2025routine reviewLatest

Routine policy review; no clinical content changes — previous version CS2O24DOO81M archived.

References: See the policy reference list for full citations, including product package inserts and guideline publications referenced in this document.

Policy Summary

PayerUnitedHealthcare

PolicyIntra-articular Sodium Hyaluronate (Viscosupplementation) for Knee Osteoarthritis

Policy CodePolicy CS2O25DOO81N

Change TypeRoutine reviewno material content changes

Effective DateJul 1, 2025

Next Review Date

SourceLink

On This Page

Small trials report symptomatic improvement for ankle OA but evidence quality is low and inconsistent; systematic reviews conclude there is insufficient data to support routine use and some guidance (NICE) advises against offering IA hyaluronan for OA.

Rheumatoid arthritis (RA): Available small trials and meta‑analyses suggest limited and inconsistent short‑term benefit of HA in some joints; larger, higher‑quality studies are needed to establish efficacy in RA.

Glottic (vocal fold) insufficiency: HA injection laryngoplasty has demonstrated improvements in voice‑related outcomes in randomized and prospective series and can provide temporary medialization (often months); evidence supports its use as an option for unilateral vocal fold paralysis though comparative high‑quality data are limited.

Cosmetic soft‑tissue augmentation: Use of sodium hyaluronate to fill contours, depressions, acne scars, or wrinkles is cosmetic and not a covered functional indication.

temporary benefit ~4–6 months

Use in the larynx is off‑label.

Documentation required for reauthorizationDocumentation of positive clinical response to prior hyaluronan therapy and recurrence of pain

Authorization scope for continuationContinuing authorization is for a single‑injection course once per joint for 6 months (per policy)

Pain VAS eligibility used in trials

Example trial pain threshold (trial inclusion)Pain score > 40 mm on a visual analog scale (VAS) used in hip OA RCTs as an eligibility example

Severity documentation relevanceStudies often required specific symptom thresholds (e.g., VAS) and imaging grade (e.g., Kellgren/Lawrence) for enrollment

Use in authorizationSymptom severity (e.g., VAS) may be requested as part of prior authorization documentation

Provide Kellgren/Lawrence grade from imaging when applicable.

Provide notes showing trial and inadequate response or intolerance to conservative therapy (see step therapy callout).

Documentation Required

Document Product and Regimen per FDA Labeling

Prior authorization requests must state the specific HA product and the exact injection regimen consistent with FDA-approved labeling. Single-injection and multi-injection products have different labeled courses of treatment and authorization will be reviewed against those regimens.

Specify product name (e.g., Durolane, Euflexxa, Gel-One, GenVisc 850, Hyalgan, Orthovisc, Synvisc/Synvisc-One, Monovisc, etc.).
Specify number of injections and interval per FDA labeling for the product requested.

Prior Authorization

Verify Prior Authorization Per Contract

Verify prior authorization requirements and any product restrictions per the member's contract and applicable state/federal rules before submission. Contractual or state-specific exceptions may supersede this policy.

Check member-specific benefit plan, state mandates, and Medicaid/Medicare contract terms for PA exceptions or variations.
If a conflict exists, follow federal/state/contractual requirements as applicable.

Denial Risk

Coverage Contingent on Indication, Dosing, and Interval

Coverage for sodium hyaluronate is contingent on indication (knee osteoarthritis), dosing, and dosing interval consistent with FDA-approved labeling. Requests that do not document appropriate indication or that propose dosing outside the labeled course may be denied.

Coverage limited to knee OA when criteria are met; other indications (e.g., hip, ankle, TMJ) are generally not covered due to insufficient evidence.
Authorization continued only when dosing and timing align with FDA-labeled courses and reauthorization criteria (e.g., >= 6 months since prior course and documented positive prior response).

Denial Risk

Contraindication-Based Denial Risk

Do not administer IA-HA to patients with known hypersensitivity to hyaluronate preparations or avian-derived products, or to joints with active infection or skin disease at the injection site. These contraindications are grounds for denial or cancellation of authorization.

Known hypersensitivity to hyaluronate or avian allergy.
Active joint infection or skin disease at the injection/injection-site area (specific to certain products).

Step Therapy

Preferred Product Step Requirement

Preferred product step requirements apply. Members should trial preferred products (Durolane, Euflexxa, Gelsyn-3 where specified) before coverage of non-preferred sodium hyaluronate products will be approved, unless there is documented contraindication or intolerance.

Coverage for GenVisc 850, Hyalgan, Supartz, Visco-3, Hymovis, Orthovisc, Synvisc/Synvisc-One, Gel-One, Monovisc, Triluron, TriVisc, Synojoynt is contingent on meeting Preferred Product Criteria.
Members already on non-preferred products may be required to change to preferred products unless documentation shows failure, intolerance, or contraindication.

Step Therapy

Step Through Standard Non-HA Therapies

Step therapy: IA-HA is typically considered only after failure of conservative, non-HA therapies. Prior authorization must document trials of standard non-HA treatments and inadequate response or intolerance.

Conservative therapies to attempt include physical therapy, NSAIDs, acetaminophen, topical agents (e.g., capsaicin), and intra-articular corticosteroid injections.
Document at least a 3-month trial of conservative measures with lack of functional improvement, or documented intolerance.

Note

Step Therapy Context

Context: viscosupplementation with HA is generally considered after conservative measures have failed. Shared decision-making is recommended given guideline variability and mixed evidence; include this context in clinical rationale to support authorization.

Guideline recommendations vary; some guidance (e.g., ACR, NICE) recommends against or is conditional regarding IA-HA in knee OA.
Use of IA-HA is more commonly limited to symptomatic knee OA after unsuccessful conservative care.

Note

Check Applicable Benefit Requirements

Check applicable benefit requirements, including federal, state, and contractual rules, before applying this policy. UnitedHealthcare's standard policy may be modified by third-party criteria (e.g., InterQual) or by plan-specific provisions.

In the event of conflict, federal/state/contractual requirements govern coverage decisions.
Confirm use of any third-party criteria the plan employs to adjudicate PA requests.

Documentation Required

Provider Documentation and Submission Notes

Miscellaneous provider guidance: include clear medical records with diagnosis, prior therapy details, objective measures of pain and function, and documentation of prior response when applicable. Incomplete documentation may delay or prevent approval.

Include diagnosis code, dates and results of prior therapies, VAS scores, imaging reports, and prior authorization history.
For reauthorization, document prior positive clinical response and time since last course (typically >= 6 months).

Authorization must match labelingDocumentation should support product selection and number of injections consistent with FDA labeling

Hyaluronates

DefinitionHyaluronates — purified natural substances used as synovial fluid replacements to improve joint pain

Clinical roleUsed to supplement synovial fluid in degenerative joint conditions (viscosupplementation) though evidence varies by indication

Composition notePrepared HA products differ in molecular weight, cross‑linking, and source (bacterial fermentation or avian extraction)

Injection laryngoplasty (IL)

Definition and intentInjection laryngoplasty (IL) — office or EMG/LEMG‑guided injection of material (e.g., hyaluronate) into the vocal fold to medialize a paralyzed or insufficient fold and improve glottic closure and voice quality

Setting and guidanceMay be performed in the office or with EMG/LEMG guidance; often used for early or acute unilateral vocal fold paralysis

Expected durabilityEffects commonly temporary; cross‑linked HA preparations may last approximately 4–6 months and repeat injections may be required

Viscosupplementation

DefinitionViscosupplementation — intra‑articular injection of hyaluronic acid to act mechanically as a lubricant in osteoarthritic joints (commonly the knee)

Regulatory contextSeveral HA preparations are FDA approved as devices for IA treatment of knee OA in patients who have failed conservative therapy

Intended effectFunctions mechanically rather than systemically to supplement synovial fluid and potentially reduce pain/improve function

Injection laryngoplasty (IL) — HA into vocal fold

Definition and clinical intentInjection laryngoplasty (IL) with HA — injection of hyaluronate into the vocal fold to medialize a paralyzed fold and improve glottic closure and voice quality; often temporary and may require repeat injections

Evidence summaryMultiple small studies and RCTs report improved voice outcomes and quality of life with low complication rates for UVFP

Procedure contextUse in the larynx is considered off‑label for many HA products and durability varies by product formulation